As part of its ongoing effort to establish a global development network, Rubicon Research Private Limited, a leading specialty pharmaceutical company, announced the acquisition of Impopharma Canada Limited with operations in Ontario, Canada.
“I welcome the Impopharma team to the Rubicon Research family and look forward to building new projects and capabilities together”
Impopharma offers comprehensive drug product formulation and process development, as well as wide-ranging analytical testing services to the pharmaceutical industry, specializing in nasal and pulmonary drug products. Over the next several months, the Company plans to establish development plans for a mix of both internal and external development projects.
“I welcome the Impopharma team to the Rubicon Research family and look forward to building new projects and capabilities together,” said Parag Sancheti, Rubicon’s Chief Executive Officer.
The 13,000 sq. ft. Impopharma site in Concord, near Toronto, has been previously inspected by the U.S. FDA and Health Canada and will be the nasal and pulmonary development Center of Excellence in the Rubicon network.
Read More: SLAppForge Incorporates US Entity and Announces New CEO
Impopharma Canada has been merged with Rubicon Research Canada Limited, a wholly owned subsidiary of Rubicon Research Private Limited.
Read More: Equinix Completes US$175 Million Acquisition of Three Data Centers in Mexico
Comments are closed, but trackbacks and pingbacks are open.